Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 3/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30030832 | 1.00 | IDO1 (0.41) | IDO1MBOAT4ACLYPTPN1GSK3B | |
| SCHEMBL30578302 | 0.85 | IDO1 (0.42) | IDO1MBOAT4ACLYPTPN1GSK3B | |
| SCHEMBL475304 | 0.83 | IDO1 (0.41) | IDO1PTPN1GSK3BPTPN5PDE2A | |
| SCHEMBL29382636 | 0.83 | IDO1 (0.41) | IDO1PTPN1GSK3BPTPN5PDE2A | |
| SCHEMBL30149710 | 0.83 | IDO1 (0.43) | IDO1PTPN1GSK3BPTPN5PDE2A | |
| SCHEMBL1018316 | 0.83 | IDO1 (0.43) | IDO1PTPN1GSK3BPTPN5PDE2A | |
| SCHEMBL12806570 | 0.82 | MBOAT4 (0.42) | IDO1MBOAT4ACLYPTPN1GSK3B | |
| SCHEMBL31706466 | 0.82 | IDO1 (0.43) | IDO1MBOAT4ACLYPTPN5TSHR | |
| SCHEMBL147970 | 0.82 | ACLY (0.40) | IDO1MBOAT4ACLYPTPN1GSK3B | |
| SCHEMBL3690695 | 0.82 | IDO1 (0.40) | IDO1MBOAT4ACLYPTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240199589-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-6667304-B2 | Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide | LES LABORATOIRES SERVIER (FR) | 2003-12-23 | — | — | US | disclosed |
| US-20030134847-A1 | New polycyclic azaindole compounds | GUILLAUMET GERALD (FR) | 2003-07-17 | — | — | US | disclosed |
| US-20030105087-A1 | For therapy of melatoninergic disorders | GUILLAUMET GERALD (FR) | 2003-06-05 | — | — | US | disclosed |
| US-6495543-B1 | TREATING OR PREVENTING MELATONINERGIC DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-12-17 | — | — | US | disclosed |
| US-5380865-A | Halogen substituents | MAY & BAKER LIMITED (GB) | 1995-01-10 | — | — | US | disclosed |
| CN-1024887-C | 2-phenylimidazole derivative-containing pesticide | MAY & BAKER LTD (GB) | 1994-06-08 | — | — | CN | disclosed |
| US-5206257-A | Controlling plant nematodes, helminth, protozoa | MAY & BAKER LIMITED (GB) | 1993-04-27 | — | — | US | disclosed |
| CN-1030577-A | Disinsection method with 2-phenylimidazole derivative | MAY & BAKER CO LTD (GB) | 1989-01-25 | — | — | CN | disclosed |
| EP-0283173-A1 | Pesticidal method using 2-phenylimidazole derivatives | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1988-09-21 | — | — | EP | disclosed |
| US-4132737-A | ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | IDO1 3544/4885MBOAT4 448/4885ACLY 1400/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | IDO1 3378/4885MBOAT4 294/4885ACLY 355/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | IDO1 3378/4885MBOAT4 294/4885ACLY 355/4885 |
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | IDO1 4145/4885MBOAT4 317/4885ACLY 2491/4885 |
| US-20030134847-A1 | New polycyclic azaindole compounds | AZI2, DRD3, CCNI | IDO1 99/4885MBOAT4 2216/4885ACLY 4538/4885 |
| US-20030105087-A1 | For therapy of melatoninergic disorders | MTNR1A, MTNR1B, TPH1 | IDO1 70/4885MBOAT4 614/4885ACLY 4439/4885 |
| US-20240199589-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | IDO1 4145/4885MBOAT4 317/4885ACLY 2491/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | IDO1 2279/4885MBOAT4 775/4885ACLY 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.